Dr Reddy’s Gets $72m Payout From Suboxone Settlement
Indivior Will Pay Sum By March 2024 To End Infringement And Antitrust Claims
Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.
You may also be interested in...
Indivior Looks To Cement Addiction Drug Leadership With Opiant Buy
Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.
Indivior Must Disband Suboxone Sales Force, Implement Executive Pay Recoupment Program
$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.
Alvogen and Reddy’s Cleared Over US Rivals To Suboxone
Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.